|         |                                                                                                                   |
|---------|-------------------------------------------------------------------------------------------------------------------|
| • | Fourth-quarter reported net sales totaled $1.4 billion. Full fiscal-year reported net sales rose to $5.6 billion. |

|         |                                                                                                                                                                      |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Fourth-quarter GAAP earnings from continuing operations were $0.65 per diluted share. Adjusted earnings1 from continuing operations totaled $0.69 per diluted share. |

|         |                                                                                                                                                                  |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Full-year GAAP earnings from continuing operations were $1.82 per diluted share. Adjusted earnings1 from continuing operations were $2.34 per diluted share. |

|         |                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------|
| • | Company initiates adjusted earnings1 guidance for fiscal 2018 of $2.25 to $2.40 per diluted share. |

|         |                                                   |
|---------|---------------------------------------------------|
| • | Consumable dental supplies decreased 4.3 percent. |

|         |                                                                                                                                                    |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Equipment sales declined 16.9 percent, primarily due to a decrease in sales of CEREC products, partially offset by solid growth in core equipment. |

----

|         |                                                                                                                                                                       |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| • | Other services and products, primarily composed of technical service, parts and labor, software support services and office supplies were flat compared to last year. |

|         |                                              |
|---------|----------------------------------------------|
| • | Companion animal sales improved 8.3 percent. |

|         |                                                                                         |
|---------|-----------------------------------------------------------------------------------------|
| • | Production animal sales rose 8.9 percent, reflecting stronger sales across all species. |

----

|         |                                                                                    |
|---------|------------------------------------------------------------------------------------|
| • | GAAP earnings are expected to be in the range of $1.90 to $2.05 per diluted share. |

|         |                                                                                                      |
|---------|------------------------------------------------------------------------------------------------------|
| • | Non-GAAP adjusted earnings1 are expected to be in the range of $2.25 to $2.40 per diluted share. |

|         |                                                                                |
|---------|--------------------------------------------------------------------------------|
| • | Our non-GAAP adjusted earnings1 guidance excludes the after-tax impact of: |

|         |                                                                                    |
|---------|------------------------------------------------------------------------------------|
| ◦ | Deal amortization expense of approximately $25.5 million ($0.27 per diluted share) |

|         |                                                                                                         |
|---------|---------------------------------------------------------------------------------------------------------|
| ◦ | Integration and business restructuring expenses of approximately $6.4 million ($0.07 per diluted share) |

|         |                                                                                   |
|---------|-----------------------------------------------------------------------------------|
| ◦ | Transaction-related costs of approximately $0.3 million ($0.00 per diluted share) |

----

----

|                                                                                                        |
|--------------------------------------------------------------------------------------------------------|
|                                                                                                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                                                                                                   | Three Months Ended |   | Twelve Months Ended |
|                                                                                                   | April 29, 2017 |   | April 30, 2016 |   | April 29, 2017 |   | April 30, 2016 |
|                                                                                                   |   |   |   |   |   |   |   |
| Net sales                                                                                              | $ | 1,445,032 |  |   | $ | 1,453,770 |  |   | $ | 5,593,127 |  |   | $ | 5,386,703 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Gross profit                                                                                           | 335,498 |  |   | 363,741 |  |   | 1,301,397 |  |   | 1,322,748 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Operating expenses                                                                                     | 239,343 |  |   | 257,397 |  |   | 1,013,469 |  |   | 975,035 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Operating income from continuing operations                                                            | 96,155 |  |   | 106,344 |  |   | 287,928 |  |   | 347,713 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Other income and expense:                                                                              |   |   |   |   |   |   |   |
| Other income, net                                                                                      | 1,033 |  |   | 1,591 |  |   | 6,013 |  |   | 4,045 |  |
| Interest expense                                                                                       | (11,401 | ) |   | (10,134 | ) |   | (43,060 | ) |   | (50,065 | ) |
|                                                                                                   |   |   |   |   |   |   |   |
| Income from continuing operations before taxes                                                         | 85,787 |  |   | 97,801 |  |   | 250,881 |  |   | 301,693 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Income tax expense                                                                                     | 24,430 |  |   | 32,181 |  |   | 77,093 |  |   | 116,009 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Net income from continuing operations                                                                  | 61,357 |  |   | 65,620 |  |   | 173,788 |  |   | 185,684 |  |
| Net income (loss) from discontinued operations                                                         | 334 |  |   | — |  |   | (2,895 | ) |   | 1,500 |  |
| Net income                                                                                             | $ | 61,691 |  |   | $ | 65,620 |  |   | $ | 170,893 |  |   | $ | 187,184 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Basic earnings (loss) per share:                                                                       |   |   |   |   |   |   |   |
| Continuing operations                                                                                  | $ | 0.65 |  |   | $ | 0.69 |  |   | $ | 1.83 |  |   | $ | 1.91 |  |
| Discontinued operations                                                                                | 0.01 |  |   | — |  |   | (0.03 | ) |   | 0.02 |  |
|             Net basic earnings per share   | $ | 0.66 |  |   | $ | 0.69 |  |   | $ | 1.80 |  |   | $ | 1.93 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Diluted earnings (loss) per share:                                                                     |   |   |   |   |   |   |   |
| Continuing operations                                                                                  | $ | 0.65 |  |   | $ | 0.68 |  |   | $ | 1.82 |  |   | $ | 1.90 |  |
| Discontinued operations                                                                                | — |  |   | — |  |   | (0.03 | ) |   | 0.01 |  |
|             Net diluted earnings per share | $ | 0.65 |  |   | $ | 0.68 |  |   | $ | 1.79 |  |   | $ | 1.91 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Shares:                                                                                                |   |   |   |   |   |   |   |
|    Basic                                                                                | 93,830 |  |   | 95,460 |  |   | 94,897 |  |   | 97,222 |  |
|    Diluted                                                                              | 94,503 |  |   | 96,121 |  |   | 95,567 |  |   | 97,902 |  |
|                                                                                                   |   |   |   |   |   |   |   |
| Dividends declared per common share                                                                    | $ | 0.26 |  |   | $ | 0.24 |  |   | $ | 0.98 |  |   | $ | 0.90 |  |

----

|                                                                                                              |
|--------------------------------------------------------------------------------------------------------------|
|                                                                                                              |  |  |  |  |  |  |  |
|                                                                                                         | April 29, 2017 |   | April 30, 2016 |
|                                                                                                         | (Unaudited) |   |   |
| ASSETS                                                                                                       |   |   |   |
| Current assets:                                                                                              |   |   |   |
| Cash and cash equivalents                                                                                    | $ | 94,959 |  |   | $ | 137,453 |  |
| Receivables                                                                                                  | 884,803 |  |   | 796,693 |  |
| Inventory                                                                                                    | 711,903 |  |   | 722,140 |  |
| Prepaid expenses and other current assets                                                                    | 111,928 |  |   | 91,255 |  |
|            Total current assets                       | 1,803,593 |  |   | 1,747,541 |  |
| Property and equipment, net                                                                                  | 298,452 |  |   | 293,315 |  |
| Goodwill and other intangible assets                                                                         | 1,238,983 |  |   | 1,325,889 |  |
| Long-term receivables, net and other                                                                         | 166,885 |  |   | 154,059 |  |
|            Total assets                               | $ | 3,507,913 |  |   | $ | 3,520,804 |  |
|                                                                                                         |   |   |   |
| LIABILITIES AND STOCKHOLDERS' EQUITY                                                                         |   |   |   |
| Current liabilities:                                                                                         |   |   |   |
| Accounts payable                                                                                             | $ | 616,859 |  |   | $ | 566,253 |  |
| Other accrued liabilities                                                                                    | 213,318 |  |   | 226,582 |  |
| Current maturities of long-term debt                                                                         | 14,754 |  |   | 16,500 |  |
| Borrowings on revolving credit                                                                               | 59,000 |  |   | 20,000 |  |
|            Total current liabilities                  | 903,931 |  |   | 829,335 |  |
| Long-term debt                                                                                               | 998,272 |  |   | 1,022,155 |  |
| Other non-current liabilities                                                                                | 211,277 |  |   | 227,568 |  |
|            Total liabilities                          | 2,113,480 |  |   | 2,079,058 |  |
| Stockholders' equity                                                                                         | 1,394,433 |  |   | 1,441,746 |  |
|            Total liabilities and stockholders' equity | $ | 3,507,913 |  |   | $ | 3,520,804 |  |

----

|                                                                                                              |
|--------------------------------------------------------------------------------------------------------------|
|                                                                                                              |  |  |  |  |  |  |  |
|                                                                                                         | Twelve Months Ended |
|                                                                                                         | April 29, 2017 |   | April 30, 2016 |
|                                                                                                         |   |   |   |
| Operating activities:                                                                                        |   |   |   |
| Net income                                                                                                   | $ | 170,893 |  |   | $ | 187,184 |  |
| Net income (loss) from discontinued operations                                                               | (2,895 | ) |   | 1,500 |  |
| Net income from continuing operations                                                                        | 173,788 |  |   | 185,684 |  |
| Adjustments to reconcile net income from continuing operations to net cash provided by operating activities: |   |   |   |
| Depreciation and amortization                                                                                | 83,818 |  |   | 82,383 |  |
| Intangible asset impairment                                                                                  | 36,312 |  |   | — |  |
| Non-cash employee compensation                                                                               | 17,710 |  |   | 28,851 |  |
| Change in assets and liabilities, net of acquired                                                            | (146,014 | ) |   | (102,045 | ) |
| Net cash provided by operating activities- continuing operations                                             | 165,614 |  |   | 194,873 |  |
| Net cash used in operating activities- discontinued operations                                               | (2,895 | ) |   | (38,544 | ) |
| Net cash provided by operating activities                                                                    | 162,719 |  |   | 156,329 |  |
| Investing activities:                                                                                        |   |   |   |
| Additions to property and equipment                                                                          | (47,019 | ) |   | (79,354 | ) |
| Acquisitions and equity investments, net of cash assumed                                                     | — |  |   | (1,106,583 | ) |
| Proceeds from sale of securities                                                                             | — |  |   | 48,744 |  |
| Other investing activities                                                                                   | 48,212 |  |   | 22,320 |  |
| Net cash provided by (used in) investing activities- continuing operations                                   | 1,193 |  |   | (1,114,873 | ) |
| Net cash provided by investing activities- discontinued operations                                           | — |  |   | 714,239 |  |
| Net cash provided by (used in) investing activities                                                          | 1,193 |  |   | (400,634 | ) |
| Financing activities:                                                                                        |   |   |   |
| Dividends paid                                                                                               | (95,910 | ) |   | (90,597 | ) |
| Repurchases of common stock                                                                                  | (125,384 | ) |   | (200,000 | ) |
| Proceeds from issuance of long-term debt, net                                                                | — |  |   | 988,400 |  |
| Debt amendment costs                                                                                         | (1,266 | ) |   | — |  |
| Retirement of long-term debt                                                                                 | (26,238 | ) |   | (682,375 | ) |
| Draw on revolver                                                                                             | 39,000 |  |   | 20,000 |  |
| Other financing activities                                                                                   | 7,635 |  |   | 7,441 |  |
| Net cash provided by (used in) financing activities                                                          | (202,163 | ) |   | 42,869 |  |
| Effect of exchange rate changes on cash                                                                      | (4,243 | ) |   | (8,371 | ) |
| Net change in cash and cash equivalents                                                                      | $ | (42,494 | ) |   | $ | (209,807 | ) |

----

|                        |
|------------------------|
|                        |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                   | April 29, 2017 |   | April 30, 2016 |   | TotalSalesGrowth |   | ForeignExchangeImpact |   | Animal HealthInternationalImpact |   | InternalGrowth |
| Three Months Ended     |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 1,148,337 |  |   | $ | 1,111,287 |  |   | 3.3 |  % |   | (1.8 | )% |   | — |  % |   | 5.1 |  % |
| Equipment and software | 207,339 |  |   | 246,930 |  |   | (16.0 | ) |   | (0.1 | ) |   | — |  |   | (15.9 | ) |
| Other                  | 89,356 |  |   | 95,553 |  |   | (6.5 | ) |   | (0.7 | ) |   | — |  |   | (5.8 | ) |
| Total                  | $ | 1,445,032 |  |   | $ | 1,453,770 |  |   | (0.6 | )% |   | (1.4 | )% |   | — |  % |   | 0.8 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 339,398 |  |   | $ | 354,563 |  |   | (4.3 | )% |   | — |  % |   | — |  % |   | (4.3 | )% |
| Equipment and software | 194,493 |  |   | 234,222 |  |   | (17.0 | ) |   | (0.1 | ) |   | — |  |   | (16.9 | ) |
| Other                  | 73,417 |  |   | 73,359 |  |   | 0.1 |  |   | (0.1 | ) |   | — |  |   | 0.2 |  |
| Total                  | $ | 607,308 |  |   | $ | 662,144 |  |   | (8.3 | )% |   | (0.1 | )% |   | — |  % |   | (8.2 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 808,939 |  |   | $ | 756,724 |  |   | 6.9 |  % |   | (2.6 | )% |   | — |  % |   | 9.5 |  % |
| Equipment and software | 12,846 |  |   | 12,708 |  |   | 1.1 |  |   | (0.2 | ) |   | — |  |   | 1.3 |  |
| Other                  | 5,687 |  |   | 11,354 |  |   | (49.9 | ) |   | (5.3 | ) |   | — |  |   | (44.6 | ) |
| Total                  | $ | 827,472 |  |   | $ | 780,786 |  |   | 6.0 |  % |   | (2.6 | )% |   | — |  % |   | 8.6 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 10,252 |  |   | $ | 10,840 |  |   | (5.4 | )% |   | — |  % |   | — |  % |   | (5.4 | )% |
| Total                  | $ | 10,252 |  |   | $ | 10,840 |  |   | (5.4 | )% |   | — |  % |   | — |  % |   | (5.4 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Twelve Months Ended    |   |   |   |   |   |   |   |   |   |   |   |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated net sales |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 4,400,888 |  |   | $ | 4,153,921 |  |   | 5.9 |  % |   | (2.1 | )% |   | 4.7 |  % |   | 3.3 |  % |
| Equipment and software | 834,526 |  |   | 857,001 |  |   | (2.6 | ) |   | — |  |   | — |  |   | (2.6 | ) |
| Other                  | 357,713 |  |   | 375,781 |  |   | (4.8 | ) |   | (0.7 | ) |   | — |  |   | (4.1 | ) |
| Total                  | $ | 5,593,127 |  |   | $ | 5,386,703 |  |   | 3.8 |  % |   | (1.7 | )% |   | 3.6 |  % |   | 1.9 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Dental                 |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 1,321,764 |  |   | $ | 1,378,886 |  |   | (4.1 | )% |   | (0.1 | )% |   | — |  % |   | (4.0 | )% |
| Equipment and software | 780,868 |  |   | 806,993 |  |   | (3.2 | ) |   | — |  |   | — |  |   | (3.2 | ) |
| Other                  | 287,587 |  |   | 290,355 |  |   | (1.0 | ) |   | — |  |   | — |  |   | (1.0 | ) |
| Total                  | $ | 2,390,219 |  |   | $ | 2,476,234 |  |   | (3.5 | )% |   | — |  % |   | — |  % |   | (3.5 | )% |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Animal Health          |   |   |   |   |   |   |   |   |   |   |   |
| Consumable             | $ | 3,079,124 |  |   | $ | 2,775,035 |  |   | 11.0 |  % |   | (3.1 | )% |   | 7.0 |  % |   | 7.1 |  % |
| Equipment and software | 53,658 |  |   | 50,008 |  |   | 7.3 |  |   | (0.2 | ) |   | — |  |   | 7.5 |  |
| Other                  | 27,044 |  |   | 37,206 |  |   | (27.3 | ) |   | (7.2 | ) |   | (0.5 | ) |   | (19.6 | ) |
| Total                  | $ | 3,159,826 |  |   | $ | 2,862,249 |  |   | 10.4 |  % |   | (3.1 | )% |   | 6.8 |  % |   | 6.7 |  % |
|                   |   |   |   |   |   |   |   |   |   |   |   |
| Corporate              |   |   |   |   |   |   |   |   |   |   |   |
| Other                  | $ | 43,082 |  |   | $ | 48,220 |  |   | (10.7 | )% |   | — |  % |   | — |  % |   | (10.7 | )% |
| Total                  | $ | 43,082 |  |   | $ | 48,220 |  |   | (10.7 | )% |   | — |  % |   | — |  % |   | (10.7 | )% |

----

|                         |
|-------------------------|
|                         |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|                    | Three Months Ended |   | Twelve Months Ended |
|                    | April 29, 2017 |   | April 30, 2016 |   | April 29, 2017 |   | April 30, 2016 |
|                    |   |   |   |   |   |   |   |
| Operating income (loss) |   |   |   |   |   |   |   |
| Dental                  | $ | 86,315 |  |   | $ | 88,722 |  |   | $ | 263,671 |  |   | $ | 312,176 |  |
| Animal Health           | 27,672 |  |   | 30,210 |  |   | 88,132 |  |   | 94,318 |  |
| Corporate               | (17,832 | ) |   | (12,588 | ) |   | (63,875 | ) |   | (58,781 | ) |
| Total                   | $ | 96,155 |  |   | $ | 106,344 |  |   | $ | 287,928 |  |   | $ | 347,713 |  |

----

|                                                |
|------------------------------------------------|
|                                                |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| For the three months ended April 29, 2017      |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Discrete tax matters |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 96,155 |  |   | $ | 178 |  |   | $ | 9,745 |  |   | $ | — |  |   | $ | 257 |  |   | $ | — |  |   | $ | — |  |   | $ | 106,335 |  |
| Other expense, net                             |   | (10,368 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (10,368 | ) |
| Income from continuing operations before taxes |   | 85,787 |  |   | 178 |  |   | 9,745 |  |   | — |  |   | 257 |  |   | — |  |   | — |  |   | 95,967 |  |
| Income tax expense                             |   | 24,430 |  |   | 67 |  |   | 3,375 |  |   | — |  |   | 98 |  |   | — |  |   | 2,383 |  |   | 30,353 |  |
| Net income from continuing operations          |   | $ | 61,357 |  |   | $ | 111 |  |   | $ | 6,370 |  |   | $ | — |  |   | $ | 159 |  |   | $ | — |  |   | $ | (2,383 | ) |   | $ | 65,614 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.65 |  |   | $ | — |  |   | $ | 0.07 |  |   | $ | — |  |   | $ | — |  |   | $ | — |  |   | $ | (0.03 | ) |   | $ | 0.69 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 6.7 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 7.4 | % |
| Effective tax rate                             |   | 28.5 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 31.6 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the three months ended April 30, 2016      |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Discrete tax matters |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 106,344 |  |   | $ | 567 |  |   | $ | 10,779 |  |   | $ | — |  |   | $ | 1,948 |  |   | $ | — |  |   | $ | — |  |   | $ | 119,638 |  |
| Other expense, net                             |   | (8,543 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (8,543 | ) |
| Income from continuing operations before taxes |   | 97,801 |  |   | 567 |  |   | 10,779 |  |   | — |  |   | 1,948 |  |   | — |  |   | — |  |   | 111,095 |  |
| Income tax expense                             |   | 32,181 |  |   | 214 |  |   | 3,869 |  |   | — |  |   | 736 |  |   | — |  |   | — |  |   | 37,000 |  |
| Net income from continuing operations          |   | $ | 65,620 |  |   | $ | 353 |  |   | $ | 6,910 |  |   | $ | — |  |   | $ | 1,212 |  |   | $ | — |  |   | $ | — |  |   | $ | 74,095 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 0.68 |  |   | $ | — |  |   | $ | 0.07 |  |   | $ | — |  |   | $ | 0.01 |  |   | $ | — |  |   | $ | — |  |   | $ | 0.77 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 7.3 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 8.2 | % |
| Effective tax rate                             |   | 32.9 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 33.3 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the twelve months ended April 29, 2017     |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Discrete tax matters |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 287,928 |  |   | $ | 1,657 |  |   | $ | 39,957 |  |   | $ | 36,312 |  |   | $ | 6,561 |  |   | $ | — |  |   | $ | — |  |   | $ | 372,415 |  |
| Other expense, net                             |   | (37,047 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | — |  |   | (37,047 | ) |
| Income from continuing operations before taxes |   | 250,881 |  |   | 1,657 |  |   | 39,957 |  |   | 36,312 |  |   | 6,561 |  |   | — |  |   | — |  |   | 335,368 |  |
| Income tax expense                             |   | 77,093 |  |   | 625 |  |   | 13,769 |  |   | 13,263 |  |   | 2,481 |  |   | — |  |   | 4,789 |  |   | 112,020 |  |
| Net income from continuing operations          |   | $ | 173,788 |  |   | $ | 1,032 |  |   | $ | 26,188 |  |   | $ | 23,049 |  |   | $ | 4,080 |  |   | $ | — |  |   | $ | (4,789 | ) |   | $ | 223,348 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 1.82 |  |   | $ | 0.01 |  |   | $ | 0.27 |  |   | $ | 0.24 |  |   | $ | 0.04 |  |   | $ | — |  |   | $ | (0.05 | ) |   | $ | 2.34 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 5.1 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 6.7 | % |
| Effective tax rate                             |   | 30.7 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 33.4 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| For the twelve months ended April 30, 2016     |   | GAAP |   | Transaction-related costs |   | Deal amortization |   | Intangible asset impairment |   | Integration and business restructuring expenses |   | Accelerated debt issuance costs |   | Discrete tax matters |   | Non-GAAP |
| Operating income from continuing operations    |   | $ | 347,713 |  |   | $ | 13,699 |  |   | $ | 39,468 |  |   | $ | — |  |   | $ | 7,144 |  |   | $ | — |  |   | $ | — |  |   | $ | 408,024 |  |
| Other expense, net                             |   | (46,020 | ) |   | — |  |   | — |  |   | — |  |   | — |  |   | 5,153 |  |   | — |  |   | (40,867 | ) |
| Income from continuing operations before taxes |   | 301,693 |  |   | 13,699 |  |   | 39,468 |  |   | — |  |   | 7,144 |  |   | 5,153 |  |   | — |  |   | 367,157 |  |
| Income tax expense                             |   | 116,009 |  |   | 3,339 |  |   | 14,051 |  |   | — |  |   | 2,701 |  |   | 1,948 |  |   | (12,300 | ) |   | 125,748 |  |
| Net income from continuing operations          |   | $ | 185,684 |  |   | $ | 10,360 |  |   | $ | 25,417 |  |   | $ | — |  |   | $ | 4,443 |  |   | $ | 3,205 |  |   | $ | 12,300 |  |   | $ | 241,409 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Diluted EPS from continuing operations*        |   | $ | 1.90 |  |   | $ | 0.11 |  |   | $ | 0.26 |  |   | $ | — |  |   | $ | 0.05 |  |   | $ | 0.03 |  |   | $ | 0.13 |  |   | $ | 2.47 |  |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Consolidated operating income as a % of sales  |   | 6.5 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 7.6 | % |
| Effective tax rate                             |   | 38.5 | % |   |   |   |   |   |   |   |   |   |   |   |   |   | 34.2 | % |
|                                           |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| * May not sum due to rounding                  |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |